Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
about
Creating an effective clinical registry for rare diseasesBrazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverRisk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialistsStratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study.Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic AcidCase-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.Obeticholic acid for the treatment of primary biliary cirrhosis.The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis.The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti-gp210.Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis.The Clinical Significance of GP73 in Immunologically Mediated Chronic Liver Diseases: Experimental Data and Literature Review.Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response.Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.Concomitant nonalcoholic fatty liver disease does not alter the activity, severity or course of primary biliary cholangitis.A brief review on prognostic models of primary biliary cholangitis.Platelet count to spleen thickness ratio is related to histologic severity of primary biliary cholangitis.The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.Serum Autotaxin Is a Useful Disease Progression Marker in Patients with Primary Biliary Cholangitis.Biomarkers for primary biliary cholangitis: current perspectives.
P2860
Q26741126-ACC04D4B-F74C-4CC7-B0CB-C6E467660D27Q26766699-9820C838-3BD7-4488-A713-E67CD92F30C6Q26796355-17CE4C64-EF2F-424A-A77C-80AEB7ED6037Q33419647-4F604E73-5210-460B-9EF9-F0872A1F41E1Q33920325-6FFDF9E4-EB45-45EA-9011-B8086EE756A0Q36193470-CC40BA3E-41CD-4069-81BC-EE6BB300FBC7Q38628470-D9C60C93-1C5E-446D-8A74-D5492BFA357AQ40681087-5D384CBE-EE7D-4A96-B821-4BBFBE768107Q41009473-CEB7BD81-8E44-49F6-B5FD-0847F6D992A6Q41303819-D635015D-7617-4302-94AC-CAB082728D72Q46813053-BF01587F-C78C-41BC-8659-B2E6E01EA870Q47114292-9472344B-F13C-4171-A12F-963E9E7E61CCQ47278009-156AF54E-15C7-45B5-B137-CF18C32E7160Q47615113-55399885-F48A-48BC-9D23-8BA77D7F99E5Q47787189-2E4C12C6-258B-41E2-ACE7-4C620F36ED56Q48200680-DFA65D09-6F87-459A-B2C0-5870F2D9C878Q48342063-46D3EEEF-A01B-48EC-9D34-0DEC074BC213Q50003369-0E82D997-BA0A-442B-8B51-FFA6AADBA89BQ52624982-9E2A366F-753D-4DDA-8435-44ADB45F4829Q55009231-27D51046-F83C-4068-8B7A-438092212A13Q55324101-2BBFA5E2-AD82-4140-B778-6DF3DEAC04F0
P2860
Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Optimising risk stratification ...... ursodeoxycholic acid response.
@en
Optimising risk stratification ...... ursodeoxycholic acid response.
@nl
type
label
Optimising risk stratification ...... ursodeoxycholic acid response.
@en
Optimising risk stratification ...... ursodeoxycholic acid response.
@nl
prefLabel
Optimising risk stratification ...... ursodeoxycholic acid response.
@en
Optimising risk stratification ...... ursodeoxycholic acid response.
@nl
P2093
P1476
Optimising risk stratification ...... ursodeoxycholic acid response
@en
P2093
Andreas Stallmach
Angela Cheung
Catalina Coltescu
Christopher Corbett
Clemens Kittler
Dhiraj Tripathi
Harry L A Janssen
Husnain Shah
James Neuberger
P304
P356
10.1016/J.JHEP.2014.01.029
P577
2014-02-15T00:00:00Z